Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA3-17 in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07623681Phase 1Not yet recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA3-17 in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by PersonGen BioTherapeutics. Primary endpoints: Maximum Tolerated Dose at 2 years and Dose-Limiting Toxicity at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
PA3-17
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07623681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623681.